Mike D Shelley

Summary

Affiliation: University Hospital of Wales
Country: UK

Publications

  1. ncbi A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
    M D Shelley
    Cochrane Prostatic Diseases and Urological Cancer Subgroup, Cancer Research Wales Laboratories, Velindre NHS Trust, Whitchurch, Cardiff CF14 2TL, Wales, UK
    BJU Int 88:209-16. 2001
  2. ncbi Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses
    Mike D Shelley
    Cochrane Unit, Research Department, Velindre NHS Trust, Whitchurch, Cardiff, Wales CF14 2TL, UK
    Cancer Treat Rev 36:195-205. 2010
  3. ncbi Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review
    M D Shelley
    Cochrane Unit, Research Department, Cardiff, Wales, UK
    Cancer Treat Rev 28:237-53. 2002
  4. ncbi Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials
    M D Shelley
    Cochrane Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff CF14 2TL, UK
    Cancer Treat Rev 35:540-6. 2009
  5. ncbi Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
    M D Shelley
    Cochrane Prostatic Diseases and Urologic Cancers Group, Velindre NHS Trust, Cardiff, UK
    BJU Int 93:485-90. 2004
  6. ncbi A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
    M D Shelley
    Cochrane Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff, Wales CF14 2TL, UK
    Cancer Treat Rev 35:9-17. 2009
  7. ncbi Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis
    Simon I R Noble
    Department of Palliative Medicine, Cardiff University, Royal Gwent Hospital, Newport, UK
    Lancet Oncol 9:577-84. 2008
  8. ncbi Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
    Mike D Shelley
    Cochrane Prostatic Diseases and Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff, UK
    BJU Int 109:496-505. 2012
  9. ncbi Surgery versus radiotherapy for muscle invasive bladder cancer?
    M D Shelley
    Clin Oncol (R Coll Radiol) 15:167-8. 2003
  10. ncbi A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?
    M D Shelley
    Cochrane Prostatic Diseases and Urological Cancers Group, Cochrane Unit, Velindre NHS Trust, Cardiff, UK
    Clin Oncol (R Coll Radiol) 16:166-71. 2004

Collaborators

Detail Information

Publications11

  1. ncbi A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
    M D Shelley
    Cochrane Prostatic Diseases and Urological Cancer Subgroup, Cancer Research Wales Laboratories, Velindre NHS Trust, Whitchurch, Cardiff CF14 2TL, Wales, UK
    BJU Int 88:209-16. 2001
    ..To assess, in a systematic review, the effectiveness of intravesical bacillus Calmette-Guérin (BCG) in preventing tumour recurrence in patients with medium/high risk Ta and T1 bladder cancer...
  2. ncbi Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses
    Mike D Shelley
    Cochrane Unit, Research Department, Velindre NHS Trust, Whitchurch, Cardiff, Wales CF14 2TL, UK
    Cancer Treat Rev 36:195-205. 2010
    ..Commonly used intravesical agents include immunotherapy with BCG and chemotherapy with cytotoxics such as Mitomycin C, Adriamycin, Epirubicin and Gemcitabine. However, controversy exists as to which agent and schedule should be used...
  3. ncbi Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review
    M D Shelley
    Cochrane Unit, Research Department, Cardiff, Wales, UK
    Cancer Treat Rev 28:237-53. 2002
    ..This article comprehensively reviews the treatment of testicular germ cell cancer with emphasis on high-grade evidence from randomised controlled trials...
  4. ncbi Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials
    M D Shelley
    Cochrane Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff CF14 2TL, UK
    Cancer Treat Rev 35:540-6. 2009
    ..We performed a systematic review of published randomised trials to assess the effectiveness of AHT...
  5. ncbi Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
    M D Shelley
    Cochrane Prostatic Diseases and Urologic Cancers Group, Velindre NHS Trust, Cardiff, UK
    BJU Int 93:485-90. 2004
    ....
  6. ncbi A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
    M D Shelley
    Cochrane Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff, Wales CF14 2TL, UK
    Cancer Treat Rev 35:9-17. 2009
    ..We performed a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer to assess the effectiveness of this therapy...
  7. ncbi Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis
    Simon I R Noble
    Department of Palliative Medicine, Cardiff University, Royal Gwent Hospital, Newport, UK
    Lancet Oncol 9:577-84. 2008
    ..Ultimately, the decision to initiate, continue, and stop anticoagulation will need to be made on an individual basis, guided by the available evidence, the patient's circumstances, and their informed preferences...
  8. ncbi Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
    Mike D Shelley
    Cochrane Prostatic Diseases and Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff, UK
    BJU Int 109:496-505. 2012
    ..Intravesical gemcitabine is a promising drug that may add to the urologist's options in treating patients with NMIBC...
  9. ncbi Surgery versus radiotherapy for muscle invasive bladder cancer?
    M D Shelley
    Clin Oncol (R Coll Radiol) 15:167-8. 2003
  10. ncbi A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?
    M D Shelley
    Cochrane Prostatic Diseases and Urological Cancers Group, Cochrane Unit, Velindre NHS Trust, Cardiff, UK
    Clin Oncol (R Coll Radiol) 16:166-71. 2004
    ..The objective of this review was to compare the overall survival after radical surgery (cystectomy) with radical radiotherapy in patients with muscle-invasive cancer...
  11. ncbi Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomised trials
    W M Sze
    Departament of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, PR China
    Clin Oncol (R Coll Radiol) 15:345-52. 2003
    ..However, the re-treatment rate and pathological fracture rate were higher after single fraction radiotherapy. Studies with quality of life and health economic end points are warranted to find out the optimal treatment option...